Cargando…

Covariate effects and population pharmacokinetic analysis of the anti-FGFR2b antibody bemarituzumab in patients from phase 1 to phase 2 trials

PURPOSE: A population pharmacokinetic (PK) analysis of the anti-fibroblast growth factor receptor 2b antibody, bemarituzumab, was performed to evaluate the impact of covariates on the PK and assess whether dose adjustment is necessary for a future phase 3 trial. METHODS: Serum concentration data wer...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xiang, Hong, Liu, Lucy, Gao, Yuying, Ahene, Ago, Collins, Helen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8484135/ https://www.ncbi.nlm.nih.gov/pubmed/34383128 http://dx.doi.org/10.1007/s00280-021-04333-y

Ejemplares similares

Population pharmacokinetic analysis of phase 1 bemarituzumab data to support phase 2 gastroesophageal adenocarcinoma FIGHT trial
por: Xiang, Hong, et al.
Publicado: (2020)

Preclinical characterization of bemarituzumab, an anti-FGFR2b antibody for the treatment of cancer
por: Xiang, Hong, et al.
Publicado: (2021)

Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma
por: Catenacci, Daniel V.T., et al.
Publicado: (2020)

Pharmacokinetics of Human Recombinant Anti-Botulinum Toxin Antibodies in Rats
por: Espinoza, Yero, et al.
Publicado: (2019)

Base and Covariate Population Pharmacokinetic Analyses of Dupilumab Using Phase 3 Data
por: Kovalenko, Pavel, et al.
Publicado: (2020)

Covariant phase-space quantization of the induced 2D gravity
por: Navarro-Salas, J, et al.
Publicado: (1993)

Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody–drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates
por: Lu, Dan, et al.
Publicado: (2014)

Base and Covariate Population Pharmacokinetic Analyses of Dupilumab in Adolescents and Children ≥6 to <12 Years of Age Using Phase 3 Data
por: Kovalenko, Pavel, et al.
Publicado: (2021)

Covariant phase space-quantization of the Jackiw-Teitelboim model of 2D-gravity
por: Navarro-Salas, J, et al.
Publicado: (1992)

The Influence of Normalization Weight in Population Pharmacokinetic Covariate Models
por: Goulooze, Sebastiaan C., et al.
Publicado: (2018)

Covariates of intravenous paracetamol pharmacokinetics in adults
por: Allegaert, Karel, et al.
Publicado: (2014)

Clinical Validation of the Covariates Pharmacokinetic Model for Propofol in an Adult Population
por: Hawthorne, Christopher, et al.
Publicado: (2022)

Covarying ionic conductances to emulate phase maintenance in stomatogastric neurons
por: Soofi, Wafa, et al.
Publicado: (2010)

Population pharmacokinetic and covariate analyses of intravenous trastuzumab (Herceptin(®)), a HER2-targeted monoclonal antibody, in patients with a variety of solid tumors
por: Quartino, Angelica L., et al.
Publicado: (2018)

A population pharmacokinetic and pharmacokinetic‐pharmacodynamic analysis of vupanorsen from phase I and phase II studies
por: Ahn, Jae Eun, et al.
Publicado: (2023)

Large-Scale Genome Comparison Based on Cumulative Fourier Power and Phase Spectra: Central Moment and Covariance Vector
por: Pei, Shaojun, et al.
Publicado: (2019)

Growth charts in FGFR2- and FGFR3-related faciocraniosynostoses
por: Ea, Caroline, et al.
Publicado: (2022)

Novel mutation detection of fibroblast growth factor receptor 1 (FGFR1) gene, FGFR2IIIa, FGFR2IIIb, FGFR2IIIc, FGFR3, FGFR4 gene for craniosynostosis: A prospective study in Asian Indian patient
por: Barik, Mayadhar, et al.
Publicado: (2015)

FGFR2 is overexpressed in myxoid liposarcoma and inhibition of FGFR signaling impairs tumor growth in vitro
por: Künstlinger, Helen, et al.
Publicado: (2015)

Population pharmacokinetic data analysis of three phase I studies of matuzumab, a humanised anti-EGFR monoclonal antibody in clinical cancer development
por: Kuester, K, et al.
Publicado: (2008)

Phase locking between excess spike synchrony and LFP is independent of rate covariation
por: Denker, Michael, et al.
Publicado: (2010)

Nintedanib plus letrozole in early breast cancer: a phase 0/I pharmacodynamic, pharmacokinetic, and safety clinical trial of combined FGFR1 and aromatase inhibition
por: Quintela-Fandino, Miguel, et al.
Publicado: (2019)

Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study
por: Lassman, Andrew B., et al.
Publicado: (2022)

Population Pharmacokinetic Modeling and Exposure–Response Assessment for the Antibody‐Drug Conjugate Brentuximab Vedotin in Hodgkin's Lymphoma in the Phase III ECHELON‐1 Study
por: Suri, Ajit, et al.
Publicado: (2019)

Pemigatinib in previously treated Chinese patients with locally advanced or metastatic cholangiocarcinoma carrying FGFR2 fusions or rearrangements: A phase II study
por: Shi, Guo‐Ming, et al.
Publicado: (2022)

Machine learning advances the integration of covariates in population pharmacokinetic models: Valproic acid as an example
por: Zhu, Xiuqing, et al.
Publicado: (2022)

Robust Adaptive Beamforming with Optimal Covariance Matrix Estimation in the Presence of Gain-Phase Errors
por: Yao, Di, et al.
Publicado: (2020)

Intrinsic FGFR2 and Ectopic FGFR1 Signaling in the Prostate and Prostate Cancer
por: Wang, Cong, et al.
Publicado: (2019)

The Evaluation of FGFR1, FGFR2 and FOXO1 in Orofacial Cleft Tissue
por: Goida, Jana, et al.
Publicado: (2022)

Resistance to allosteric SHP2 inhibition in FGFR-driven cancers through rapid feedback activation of FGFR
por: Lu, Hengyu, et al.
Publicado: (2020)

Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancer
por: Pegram, Mark D, et al.
Publicado: (2009)

Comparison of the ELISA and ECL Assay for Vedolizumab Anti-drug Antibodies: Assessing the Impact on Pharmacokinetics and Safety Outcomes of the Phase 3 GEMINI Trials
por: Wyant, Timothy, et al.
Publicado: (2020)

Phase 2 Study of Anti-Human Cytomegalovirus Monoclonal Antibodies for Prophylaxis in Hematopoietic Cell Transplantation
por: Maertens, Johan, et al.
Publicado: (2020)

Application of SHAP values for inferring the optimal functional form of covariates in pharmacokinetic modeling
por: Janssen, Alexander, et al.
Publicado: (2022)

Ganciclovir Pharmacokinetics and Individualized Dosing Based on Covariate in Lung Transplant Recipients
por: Dvořáčková, Eliška, et al.
Publicado: (2022)

Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study
por: Meric-Bernstam, Funda, et al.
Publicado: (2022)

Runx2 is required for the proliferation of osteoblast progenitors and induces proliferation by regulating Fgfr2 and Fgfr3
por: Kawane, Tetsuya, et al.
Publicado: (2018)

Incidence of FGFR2 Amplification and FGFR2 Fusion in Patients with Metastatic Cancer Using Clinical Sequencing
por: Hyung, Sujin, et al.
Publicado: (2022)

Pharmacokinetic Profile of a 2-Month Dose Regimen of Aripiprazole Lauroxil: A Phase I Study and a Population Pharmacokinetic Model
por: Hard, Marjie L., et al.
Publicado: (2017)

FGF2/FGFR1 regulates autophagy in FGFR1-amplified non-small cell lung cancer cells
por: Yuan, Hong, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_brl39e7qkbidq971uu66gm79dr